Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QED Therapeutics

bridgebio.com

Latest From QED Therapeutics

Guardant Health, Roche’s Foundation Medicine Receive FDA Companion Diagnostic Nods

Roche’s Foundation Medicine still leads Guardant Health in terms of total companion-diagnostic US FDA approvals as both companies announced new PMA supplements.

In Vitro Diagnostics Cancer

Helsinn And BridgeBio Ink Infigratinib Cancer Pact

Helsinn’s strategic collaboration with BridgeBio Pharma to co-develop and commercialise candidate FGFR1-3 inhibitor infigratinib in oncology will give the Swiss family-owned company its first targeted cancer therapeutic for the US market, its CEO tells Scrip.

Deals Rare Diseases

Finance Watch: Three New Life Science VC Funds Total Nearly $1bn

Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds. 

Financing StartUps and SMEs

Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register